# InspireMD Inc. (NSPR)

Source: https://www.quantisnow.com/company/NSPR
Generated: 2026-11-14T13:07:08.378Z

- Ticker: NSPR
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical/Dental Instruments
- SEC CIK: 0001433607
- Website: inspiremd.com

## About

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.

## Latest NSPR news and filings

- 2026-11-13 13:12 UTC [Public Offering] [InspireMD Announces Pricing of $37.5 Million Public Offering](https://www.quantisnow.com/insight/inspiremd-announces-pricing-of-375-million-public-offering-6789483)
- 2026-11-12 22:24 UTC [SEC Form 424B5] [SEC Form 424B5 filed by InspireMD Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-inspiremd-inc-6788855)
- 2026-11-12 21:45 UTC [SEC Form 8-K] [InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inspiremd-inc-filed-sec-form-8-k-results-of-operations-and-6788603)
- 2026-11-12 21:45 UTC [SEC Form 8-K] [InspireMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inspiremd-inc-filed-sec-form-8-k-regulation-fd-disclosure-other-6788602)
- 2026-11-12 21:15 UTC [Public Offering] [InspireMD Announces Proposed Public Offering](https://www.quantisnow.com/insight/inspiremd-announces-proposed-public-offering-6788040)
- 2026-11-12 21:03 UTC [Earnings] [InspireMD Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/inspiremd-reports-third-quarter-2026-financial-results-6787560)
- 2026-11-12 21:01 UTC [InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures](https://www.quantisnow.com/insight/inspiremd-announces-fda-approval-of-the-cguard-prime-transcarotid-stent-6787478)
- 2026-11-11 21:05 UTC [Earnings Date] [InspireMD Announces Updated Timing for Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/inspiremd-announces-updated-timing-for-third-quarter-2026-financial-results-6785447)
- 2026-10-29 12:00 UTC [Earnings Date] [InspireMD to Announce Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/inspiremd-to-announce-third-quarter-2026-financial-results-6762581)
- 2026-09-23 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Roubin Gary S](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-roubin-gary-s-6724170)
- 2026-09-23 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Berman Michael](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-berman-michael-6724152)
- 2026-09-23 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Stuka Paul](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-stuka-paul-6724137)
- 2026-09-21 13:12 UTC [SEC Form 8-K] [InspireMD Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inspiremd-inc-filed-sec-form-8-k-entry-into-a-material-6721421)
- 2026-09-03 12:00 UTC [Conference Announcement] [InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/inspiremd-to-participate-in-upcoming-hc-wainwright-28th-annual-global-6704264)
- 2026-08-17 11:05 UTC [SEC Form 8-K] [InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inspiremd-inc-filed-sec-form-8-k-results-of-operations-and-6684186)
- 2026-08-14 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by InspireMD Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-inspiremd-inc-6683224)
- 2026-08-10 20:01 UTC [Earnings Date] [InspireMD to Announce Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/inspiremd-to-announce-second-quarter-2026-financial-results-6673438)
- 2026-07-30 20:01 UTC [Leadership Update] [InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing](https://www.quantisnow.com/insight/inspiremd-appoints-carotid-intervention-commercial-leader-kathleen-kennedy-as-senior-6655888)
- 2026-07-29 21:00 UTC [SEC Form 8-K] [InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inspiremd-inc-filed-sec-form-8-k-leadership-update-financial-statements-6654215)
- 2026-07-23 21:00 UTC [SEC Form 8-K] [InspireMD Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inspiremd-inc-filed-sec-form-8-k-notice-of-delisting-or-6647443)
- 2026-07-02 21:00 UTC [SEC Form 8-K] [InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inspiremd-inc-filed-sec-form-8-k-leadership-update-financial-statements-6626250)
- 2026-06-11 12:05 UTC [SEC Form 8-K] [InspireMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inspiremd-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6598287)
- 2026-06-11 12:00 UTC [InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures](https://www.quantisnow.com/insight/inspiremd-announces-30-day-results-from-the-cguardians-ii-clinical-trial-6598210)
- 2026-06-08 12:00 UTC [InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures](https://www.quantisnow.com/insight/inspiremd-announces-first-patient-enrolled-in-the-cguardians-iii-pivotal-6592588)
- 2026-06-03 20:05 UTC [SEC Form 8-K] [InspireMD Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inspiremd-inc-filed-sec-form-8-k-amendments-to-articles-of-6586701)
- 2026-05-29 20:05 UTC [Insider Buy] [Director Stuka Paul bought $17,500 worth of shares (20,000 units at $0.88), increasing direct ownership by 3% to 667,871 units (SEC Form 4)](https://www.quantisnow.com/insight/director-stuka-paul-bought-17500-worth-of-shares-20000-units-6579019)
- 2026-05-22 20:05 UTC [SEC Form 8-K] [InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inspiremd-inc-filed-sec-form-8-k-leadership-update-financial-statements-6569611)
- 2026-05-21 21:16 UTC [SEC Form 4] [Chief Commercial Officer Gleason Shane Thomas sold $189,594 worth of shares (85,295 units at $2.22), decreasing direct ownership by 7% to 1,053,882 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/chief-commercial-officer-gleason-shane-thomas-sold-189594-worth-of-6568200)
- 2026-05-15 20:05 UTC [Insider Buy] [Director Stuka Paul bought $17,325 worth of shares (15,000 units at $1.16), increasing direct ownership by 2% to 647,871 units (SEC Form 4)](https://www.quantisnow.com/insight/director-stuka-paul-bought-17325-worth-of-shares-15000-units-6557126)
- 2026-05-13 21:00 UTC [Insider Buy] [CEO and President Slosman Marvin bought $25,200 worth of shares (21,000 units at $1.20), increasing direct ownership by 0.59% to 3,556,658 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-and-president-slosman-marvin-bought-25200-worth-of-shares-6551526)
- 2026-05-13 20:47 UTC [Insider Buy] [Amendment: Director Stuka Paul bought $88,026 worth of shares (75,626 units at $1.16), increasing direct ownership by 14% to 632,871 units (SEC Form 4)](https://www.quantisnow.com/insight/amendment-director-stuka-paul-bought-88026-worth-of-shares-75626-6551435)
- 2026-05-12 23:35 UTC [Insider Buy] [Director Stuka Paul bought $88,026 worth of shares (75,626 units at $1.16), increasing direct ownership by 14% to 632,871 units (SEC Form 4)](https://www.quantisnow.com/insight/director-stuka-paul-bought-88026-worth-of-shares-75626-units-6549190)
- 2026-05-08 21:08 UTC [Insider Buy] [Director Ward Scott R. bought $102,638 worth of shares (89,250 units at $1.15), increasing direct ownership by 60% to 237,096 units (SEC Form 4)](https://www.quantisnow.com/insight/director-ward-scott-r-bought-102638-worth-of-shares-89250-6542916)
- 2026-05-08 21:05 UTC [Insider Buy] [Director Stuka Paul bought $9,034 worth of shares (7,895 units at $1.14), increasing direct ownership by 2% to 531,599 units (SEC Form 4)](https://www.quantisnow.com/insight/director-stuka-paul-bought-9034-worth-of-shares-7895-units-6542886)
- 2026-05-08 21:03 UTC [Insider Buy] [Director Roubin Gary S bought $106,200 worth of shares (90,000 units at $1.18), increasing direct ownership by 12% to 834,478 units (SEC Form 4)](https://www.quantisnow.com/insight/director-roubin-gary-s-bought-106200-worth-of-shares-90000-6542850)
- 2026-05-07 12:53 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by InspireMD Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-inspiremd-inc-6537871)
- 2026-05-06 20:05 UTC [Conference Announcement] [InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference](https://www.quantisnow.com/insight/inspiremd-to-participate-in-upcoming-bank-of-america-securities-2026-6535202)
- 2026-05-04 20:05 UTC [SEC Form 8-K] [InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inspiremd-inc-filed-sec-form-8-k-results-of-operations-and-6528928)
- 2026-05-01 20:07 UTC [SEC Form 8-K] [InspireMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inspiremd-inc-filed-sec-form-8-k-regulation-fd-disclosure-other-6526757)
- 2026-05-01 20:05 UTC [InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System](https://www.quantisnow.com/insight/inspiremd-announces-fda-approval-of-investigational-device-exemption-application-for-6526660)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NSPR
- Earnings history: https://www.quantisnow.com/earnings/NSPR
- Dividend history: https://www.quantisnow.com/dividends/NSPR
- Insider transactions: https://www.quantisnow.com/insiders/NSPR
- Options chain: https://www.quantisnow.com/options/NSPR
- SEC 8-K filings only: https://www.quantisnow.com/company/NSPR/8-k
- RSS and alerts for NSPR: https://www.quantisnow.com/docs/rss-feeds.md